抗人表皮生长因子受体2阳性乳腺癌靶向治疗的疗效及安全性

摘要

目的 探讨抗人表皮生长因子受体2(HER2)阳性乳腺癌靶向治疗的疗效及安全性.方法 60例HER-2阳性乳腺癌患者分为对照组(EC序贯紫杉醇/多西他赛/紫杉醇脂质体化疗)和观察组(曲妥珠单抗+EC序贯紫杉醇/多西他赛/紫杉醇脂质体化疗)各30例,比较2组临床疗效及安全性.结果 治疗前2组肿瘤标志物无显著差异,治疗后观察组显著优于对照组(P＜0.05);治疗前2组肌酸磷酸激酶、LVEF无显著差异,治疗后观察组略差于对照组(P＞0.05).结论 抗HER-2阳性乳腺癌靶向治疗的疗效确切且安全性较高.%Objective To investigate the efficacy and safety of targeted therapy for breast cancer with positive anti-human epidermal growth factor receptor 2 (HER2).Methods Totally 60 breast cancer patients with positive HER-2 were divided into control group (EC sequential paclitaxel,docetaxel,paclitaxel liposomes) and observation group (trastuzumab + EC sequential paclitaxel,docetaxel,paclitaxel liposome chemotherapy),30 cases in each group.Clinical efficacy and safety were compared.Results There were no significant differences in the tumor markers between the two groups before treatment,but the tumor markers after treatment in the observation group were significantly better than the control group (P ＜ 0.05).There were no significant differences in creatine phosphokinase and LVEF between the two groups before treatment,and levels of creatine phosphokinase and LVEF after treatment in the observation group were slightly worse than the control group (P ＞ 0.05).Conclusion Targeted therapy for breast cancer with anti-positive HER-2 is effective and safe.